Willy Barton / Shutterstock.com
The UK Intellectual Property Office has agreed to revoke an extension to a supplementary protection certificate (SPC) for immunosuppressant tocilizumab, at the request of the owners.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
UKIPO, Chugai, SPC, immunosuppressant, arthritis, paediatrics, marketing exclusivity, EMA, protection, tocilizumab, European Commission, RoActemra